An interventional study of GnRH agonist downregulation and GnRH agonist and Letrozole in Adenomyosis, sponsored by Indira IVF Hospital Pvt Ltd. Not yet recruiting at 1 site in India. Open to female participants aged 21 Years to 42 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Indira IVF Hospital Pvt Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Purpose of the Study:
To compare the effectiveness of GnRH agonist downregulation alone versus GnRH agonist combined with letrozole in improving pregnancy outcomes in women with adenomyosis undergoing frozen embryo transfer (FET).
Research Question:
Is the combined use of GnRH agonist and letrozole more effective than GnRH agonist downregulation alone in achieving better ongoing pregnancy rates in adenomyosis cases undergoing FET?
Hypothesis:
Null Hypothesis (H₀): The combined use of GnRH agonist and letrozole is not more effective than GnRH agonist downregulation alone in achieving a higher ongoing pregnancy rate in adenomyosis cases undergoing FET.
Study Outcomes:
Primary Outcome: Ongoing pregnancy rate at 12 weeks of gestation.
142 studies on the registry are indexed under Adenomyosis; 54 are open to participants now.
This study's planned enrollment of 700 is above the median of 100 across 78 interventional studies indexed under Adenomyosis.
Browse Adenomyosis studies →Indira IVF Hospital Pvt Ltd is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of adenomyosis confirmed via transvaginal ultrasound as per MUSA criteria History of infertility requiring frozen embryo transfer (FET). Availability of at least one good-quality frozen embryo for transfer
Exclusion Criteria:
≥ 30 kg/m2 Presence of endocrine disorders; (uncontrolled diabetes mellitus, / hyperprolactinemia, thyroid dysfunction, Congenital adrenal hyperplasia, Cushing syndrome, or polycystic ovary syndrome Previous major uterine surgery Gestational carrier Fertility preservation
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GnRH agonist downregulation
Drug: GnRH agonist and Letrozole
Triptorelin Acetate 3.75mg for two consecutive dosage at 30 days interval
Drug pages: Gonadotropin-releasing Hormone AnalogStudies of Gonadotropin-releasing Hormone AnalogGonadotropin-releasing Hormone Analog pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LetrozoleStudies of LetrozoleLetrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Triptorelin Acetate 3.75mg for two consecutive dosages at 30 days interval) + Letrozole (5 mg once daily for a total of 21 days during the second depot - letrozole stops when Estrogen priming starts
Ongoing pregnancy rate
Presence of gestational sacs with a heartbeat at the 12th gestational week. The ongoing pregnancy rate will be calculated using the below formula. Ongoing pregnancy rate: (the number of ongoing pregnancy cases/the number of clinical pregnancy cases) × 100%
Time frame: 12 weeks of gestation
Implantation Rate
The number of gestational sacs observed by transvaginal ultrasound at the 6th gestational week per the number of embryos transferred. The implantation rate will be calculated using the below formula. Implantation rate: (The number of gestational sacs observed/ number of embryos transferred) × 100
Time frame: 4 weeks after embryo transfer
Chemical Pregnancy rate
Detection of a fetal heartbeat on transvaginal ultrasound at the 6th gestational week. The clinical pregnancy rate will be calculated using the below formula.
Time frame: 4 weeks after embryo transfer
Biochemical loss rate
Pregnancies diagnosed only by β-human chorionic gonadotropin detection without a gestational sac visualized by vaginal ultrasound at the 6th gestational week. The biochemical loss rate will be calculated using the below formula. Biochemical loss rate: (the number of biochemical pregnancy loss cases/the number of women per group) × 100%
Time frame: 4 weeks after embryo transfer
1st trimester loss
First-trimester loss refers to the spontaneous loss of a pregnancy occurring before the end of the 12th week of gestation
Time frame: 12 weeks of gestation
2nd trimester loss
Second-trimester loss refers to the spontaneous loss of a pregnancy occurring between 13 and 20 weeks of gestation.
Time frame: 20 weeks of gestation
Live Birth Rate
The number of deliveries that resulted in at least one live birth per 100 Embryo transferred cycle. Live birth rate: (The number of live births / the number of embryos transferred cycle) × 100
Time frame: Post delivery after completion of 20 weeks of gestation
Plan to share: Yes — he Individual Participant Data (IPD) will be shared with authorized researchers upon request. The supporting documents, including the study protocol, SAP, and ICF, will be provided alongside the IPD to ensure comprehensive understanding and proper data interpretation. When: IPD will be available after the completion of the study and publication of primary results. How: IPD will be shared through a secure data repository or via encrypted files sent through secure email upon request, following proper data use agreements.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: After publication
Start is estimated for Jan 2027; primary completion for Sep 2027, 7 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start Jun 2026 → Jan 2027, primary completion Jul 2026 → Sep 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gonadotropin-releasing Hormone Analog · Letrozole
Indira IVF Hospital Pvt Ltd